Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

TY - JOUR

T1 - Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

AU - Musto, Pellegrino

AU - Santini, Valeria

AU - Balestri, Francesca

AU - Fabbri, Alberto

AU - Falcone, Antonietta

AU - Sanpaolo, Grazia

N1 - Keywords: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin, Recombinant; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome

PY - 2002

Y1 - 2002

N2 - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

AB - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

M3 - Journal article

C2 - 11869946

SN - 0390-6078

VL - 87

SP - 322

EP - 323

JO - Haematologica

JF - Haematologica

IS - 3

ER -